Key Points
- CEO Bobak Azamian sold 6,000 shares at an average price of $82.51 on Dec. 24 for a total of $495,060, trimming his stake by 0.69% to 857,991 shares (≈$70.8M).
- Tarsus reported Q3 results that beat estimates—EPS of ($0.30) vs. ($0.35) consensus and revenue of $118.7M—and its lead candidate, OC-01 (varenicline) is in Phase 3
- The stock trades near the low-$80s with a market cap of about $3.49 billion, an average analyst rating of "Moderate Buy" (avg. target $79.86), and roughly 90% institutional ownership.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) CEO Bobak Azamian sold 6,000 shares of the business's stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total transaction of $495,060.00. Following the transaction, the chief executive officer owned 857,991 shares of the company's stock, valued at approximately $70,792,837.41. The trade was a 0.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
Tarsus Pharmaceuticals Stock Up 0.4%
Tarsus Pharmaceuticals stock opened at $82.33 on Wednesday. The stock has a market cap of $3.49 billion, a PE ratio of -40.76 and a beta of 0.74. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.29 and a quick ratio of 4.25. The stock's fifty day moving average is $76.57 and its two-hundred day moving average is $60.27. Tarsus Pharmaceuticals, Inc. has a 1-year low of $38.51 and a 1-year high of $85.25.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.05. The business had revenue of $118.70 million for the quarter, compared to the consensus estimate of $114.22 million. Tarsus Pharmaceuticals had a negative return on equity of 26.29% and a negative net margin of 22.17%. On average, sell-side analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
TARS has been the topic of a number of recent analyst reports. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $51.00 target price on shares of Tarsus Pharmaceuticals in a research report on Thursday, November 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a report on Wednesday, October 8th. Barclays began coverage on Tarsus Pharmaceuticals in a report on Monday, December 8th. They issued an "overweight" rating and a $100.00 target price for the company. Zacks Research raised Tarsus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Friday, September 5th. Finally, HC Wainwright increased their price objective on Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the company a "neutral" rating in a report on Monday, October 20th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $79.86.
Read Our Latest Stock Analysis on Tarsus Pharmaceuticals
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Tarsus Pharmaceuticals by 26.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company's stock valued at $66,000 after purchasing an additional 339 shares during the period. Osaic Holdings Inc. increased its stake in Tarsus Pharmaceuticals by 779.1% in the 2nd quarter. Osaic Holdings Inc. now owns 2,778 shares of the company's stock valued at $113,000 after buying an additional 2,462 shares during the period. Tower Research Capital LLC TRC increased its stake in Tarsus Pharmaceuticals by 220.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company's stock valued at $164,000 after buying an additional 2,782 shares during the period. Quarry LP raised its position in Tarsus Pharmaceuticals by 20.0% during the 1st quarter. Quarry LP now owns 3,599 shares of the company's stock worth $185,000 after buying an additional 599 shares during the last quarter. Finally, West Wealth Group LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the 3rd quarter worth $202,000. 90.01% of the stock is currently owned by hedge funds and other institutional investors.
About Tarsus Pharmaceuticals
(
Get Free Report)
Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.
In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
